Findings of a Biosimilar Trastuzumab Study in Patients with HER2-Positive Breast Cancer

Video

Francisco Esteva, director, breast medical oncology program, Perlmutter Cancer Center, NYU Langone Medical Center, discusses the findings of a biosimilar trastuzumab study in patients with HER2-positive breast cancer.

Related Videos
Video 5 - "Second-Line Treatment Considerations and Improving Outcomes in Breast Cancer"
Video 4 - "Impressions on Safety Data from EMERALD Subgroup Analysis"
Video 2 - "Importance of Biomarker Testing in Breast Cancer"
Video 3 - "EMERALD: Elacestrant for ER+/HER2- Advanced Breast Cancer"
Video 1 - "Patient Profile: A 49-Year-Old Woman with HR+/HER2- mBC and Liver and Lung Metastases"
Video 7 - "Unmet Needs and Future Directions in HER2+ Breast Cancer"
Related Content